Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has shared an announcement.
Shandong Xinhua Pharmaceutical Company Limited, a PRC-based drug maker listed in both Hong Kong and Shenzhen, has released its audited consolidated results for the financial year ended 31 December 2025, prepared in accordance with China Accounting Standards for Business Enterprises. The disclosure underscores the company’s adherence to domestic regulatory requirements and provides shareholders in both A-share and H-share markets with updated visibility into its 2025 financial performance.
The announcement also reiterates key corporate information, including its legal representative, board secretary, and principal contact and listing details. By formalizing these results and corporate particulars, Shandong Xinhua strengthens transparency and compliance practices, which are important for investor confidence and its continued positioning in China’s capital markets.
The most recent analyst rating on (HK:0719) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Shandong Xinhua Pharmaceutical Company Limited Class H stock, see the HK:0719 Stock Forecast page.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a PRC-based joint stock company engaged in the pharmaceutical industry. Listed in both Hong Kong and Shenzhen, it operates from Zibo, Shandong Province, and focuses on producing and marketing pharmaceutical products, serving domestic and international markets through its A-share and H-share listings.
Average Trading Volume: 989,077
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.46B
For an in-depth examination of 0719 stock, go to TipRanks’ Overview page.